ARPANSA’s CEO, Dr Carl-Magnus Larsson has issued a licence to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine Molybdenum-99 (Mo-99) Facility (the ANM Facility).
On Monday 26 February 2018 a report by the CEO of ARPANSA, Dr Carl-Magnus Larsson, was tabled in Parliament addressing the radiation exposure of a worker at the Australian Nuclear Science and Technology Organisation (ANSTO) Health radiopharmaceuticals production facility at Lucas Heights.
A series of animal studies on mobile phone radiofrequency radiation and health have been conducted over two years by the United States Department of Health and Human Services National Toxicology Program.
We have a commitment to good regulatory practice, so each year we self-assess our performance as a regulator. We’re doing better every year. You can now read our self-assessment for the last financial year, 2016-17.
Our 2016-17 Annual Report was tabled in parliament on Wednesday 18 October 2017. The Annual Report informs parliament, stakeholders and the community how we have enabled protection of the Australian people and environment from the harmful effects of radiation during the last financial year.